1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Solanbridge Group, Inc.

Solanbridge Group, Inc.

SLNX
Solanbridge Group, Inc.US flagOther OTC
0.00
USD
- -
- -
476,000.00Market Cap
Solanbridge Group, Inc.
SLNX
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2004
2005
2006
2007
2008
2009
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.02
-0.01
-0.02
-0.01
-0.02
-0.02
-0.02
Basic EPS, GAAP
-0.01
-0.01
-0.02
-0.01
- -
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.04
-0.04
-0.05
-0.06
-0.08
-0.1
-0.08
Book Value per Share
-0.01
-0.02
-0.02
-0.03
-0.02
-0.03
-0.03
Tangible Book Value per Share
8
8
11
12
12
12
15
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'10
Jun'10
Sep'10
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
15
15
15
Market Capitalization
1
1
1

Working Capital

FRC

•

in mil. unless spec.
Mar'10
Jun'10
Sep'10
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
47.07%
67.17%
Free Cash Flow
- -
61.75%
188.28%
Net Income, GAAP
- -
37.72%
10.49%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
-0.02
2009
- -
- -
- -
- -
-0.02
2010
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
Similar Companies
Duopharma Biotech Berhad (7148.KL)
Harrow Health, Inc. (HROW)
Aarti Pharmalabs Limited (AARTIPHARM.BO)
iPROMOMED (PRMD.ME)
Pak Fah Yeow International Limited (0239.HK)
Center Laboratories, Inc. (4123.TWO)
Business
Solanbridge Group, Inc. (SLNX) operates as a biotechnology company focused on the research, development, and production of nutraceutical and cosmetic products, with emphasis on cannabidiol (CBD) oil and related hemp-derived offerings. The company provides CBD hemp oil produced in states including Colorado, Nevada, and California; CBD-infused personal care products; and engages in the development of additional cannabinoid-based nutraceuticals and cosmetics. It targets the medical marijuana and wellness sectors, serving consumers seeking natural health and beauty solutions through its operations primarily in the United States. Founded in 2000 and headquartered in Spring, Texas, with references to locations in The Woodlands, Texas; Lakewood, Colorado; and Edgewater, Colorado, Solanbridge Group maintains a minimal operational footprint as a penny stock entity trading on OTC markets. The company, originally incorporated in Nevada and re-domiciled to Maryland in 2013, has historically pursued diversified holdings including subsidiaries like David's Steak and Seafood Restaurant and Advanced Medical Sales LLC, though current emphasis rests on biotechnology ventures. In recent developments, Solanbridge Group acquired a 51% stake in BICOM, LLC, marking a strategic expansion into associated business interests as of 2024. The company reports ongoing product development in CBD oil without notable funding rounds, partnerships, or new launches disclosed in the past 1-2 years, while maintaining its focus amid a low market capitalization of approximately $4,760.